Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species
- PMID: 14707072
- DOI: 10.4049/jimmunol.172.2.989
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species
Erratum in
- J Immunol. 2004 Apr 1;172(7):4647
Abstract
Tumor growth is associated with the accumulation of immature myeloid cells (ImC), which in mice are characterized by the expression of Gr-1 and CD11b markers. These cells suppress Ag-specific CD8+ T cells via direct cell-cell contact. However, the mechanism of immunosuppressive activity of tumor-derived ImC remains unclear. In this study we analyzed the function of ImC isolated from tumor-free control and tumor-bearing mice. Only ImC isolated from tumor-bearing mice, not those from their control counterparts, were able to inhibit the Ag-specific response of CD8+ T cells. ImC obtained from tumor-bearing mice had significantly higher levels of reactive oxygen species (ROS) than ImC isolated from tumor-free animals. Accumulation of H2O2, but not superoxide or NO, was a major contributor to this increased pool of ROS. It appears that arginase activity played an important role in H2O2 accumulation in these cells. Inhibition of ROS in ImC completely abrogated the inhibitory effect of these cells on T cells, indicating that ImC generated in tumor-bearing hosts suppress the CD8+ T cell response via production of ROS. Interaction of ImC with Ag-specific T cells in the presence of specific Ags resulted in a significant increase in ROS production compared with control Ags. That increase was independent of IFN-gamma production by T cells, but was mediated by integrins CD11b, CD18, and CD29. Blocking of these integrins with specific Abs abrogated ROS production and ImC-mediated suppression of CD8+ T cell responses. This study demonstrates a new mechanism of Ag-specific T cell inhibition mediated by ROS produced by ImCs in cancer.
Similar articles
-
Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.J Immunol. 2001 May 1;166(9):5398-406. doi: 10.4049/jimmunol.166.9.5398. J Immunol. 2001. PMID: 11313376
-
Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.J Leukoc Biol. 2003 Aug;74(2):186-96. doi: 10.1189/jlb.0103010. J Leukoc Biol. 2003. PMID: 12885935
-
Analysis of splenic Gr-1int immature myeloid cells in tumor-bearing mice.Microbiol Immunol. 2008 Jan;52(1):47-53. doi: 10.1111/j.1348-0421.2008.00009.x. Microbiol Immunol. 2008. PMID: 18352913
-
Immature myeloid cells and cancer-associated immune suppression.Cancer Immunol Immunother. 2002 Aug;51(6):293-8. doi: 10.1007/s00262-002-0280-8. Epub 2002 Apr 24. Cancer Immunol Immunother. 2002. PMID: 12111117 Free PMC article. Review.
-
Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment.Clin Cancer Res. 2012 Sep 15;18(18):4877-82. doi: 10.1158/1078-0432.CCR-11-2939. Epub 2012 Jun 19. Clin Cancer Res. 2012. PMID: 22718858 Free PMC article. Review.
Cited by
-
Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1-PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer.Cell Death Dis. 2021 May 9;12(5):465. doi: 10.1038/s41419-021-03745-1. Cell Death Dis. 2021. PMID: 33967272 Free PMC article.
-
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Immunology. 2013 Feb;138(2):105-15. doi: 10.1111/imm.12036. Immunology. 2013. PMID: 23216602 Free PMC article. Review.
-
The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors.J Immunol Res. 2015;2015:143526. doi: 10.1155/2015/143526. Epub 2015 May 3. J Immunol Res. 2015. PMID: 26064994 Free PMC article. Review.
-
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses.Cancer Immunol Res. 2021 Aug;9(8):952-966. doi: 10.1158/2326-6066.CIR-20-0834. Epub 2021 Jun 1. Cancer Immunol Res. 2021. PMID: 34074677 Free PMC article.
-
The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.Neoplasia. 2020 Nov;22(11):539-553. doi: 10.1016/j.neo.2020.08.007. Epub 2020 Sep 20. Neoplasia. 2020. PMID: 32966956 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials